VKORC1 polymorphisms in Amerindian populations of Brazil

Pharmacogenomics

Volumn 9, Issue 11, 2008, Pages 1623-1629

  Perini, Jamila A ^a   Petzl Erler, Maria Luiza ^b   Tsuneto, Luiza Tamie ^b   Suarez Kurtz, Guilherme ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Amerindian; anticoagulants; Brazil; Native American; VKORC1; warfarin

Indexed keywords

DNA; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE SUBUNIT 1; WARFARIN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE;

ADULT; AFRICAN AMERICAN; AMERICAN INDIAN; ARTICLE; ASIAN; BRAZIL; COMPUTER PROGRAM; CONTROLLED STUDY; DNA DETERMINATION; DOSE CALCULATION; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LINKAGE ANALYSIS; MUTATION RATE; MUTATIONAL ANALYSIS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; POPULATION GENETICS;

BRAZIL; GENE FREQUENCY; GENETICS, POPULATION; HAPLOTYPES; HUMANS; INDIANS, SOUTH AMERICAN; LINKAGE DISEQUILIBRIUM; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

EID: 61549104709     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.11.1623     Document Type: Article

References (30)

1. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005).
2. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5(4), 262-270 (2005). (Pubitemid 41131718)
3. DAndrea G, DAmbrosio R, Margaglione M: Oral anticoagulants: pharmacogenetics relationship between genetic and non-genetic factors. Blood Rev. 22(3), 127-140 (2008).
4. Owen RP, Altman RB, Klein TE: PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics. Hum. Mutat. 29(4), 456-460 (2008).
5. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics. 16(2), 101-110 (2006). (Pubitemid 43145678)
6. Marsh S, King CR, Porche-Sorbet RM, et al. Population variation in VKORC1 haplotype structure. J. Thromb. Haemost. 4(2), 473-474 (2006).
7. Lee SC, Ng SS, Oldenburg J, et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther. 79(3), 197-205 (2006). (Pubitemid 43297012)
8. Petzl-Erler ML, Luz R, Sotomaior VS: The HLA polymorphism of two distinctive South-American Indian tribes: the Kaingang and the Guarani. Tissue Antigens. 41(5), 227-237 (1993). (Pubitemid 23239621)
9. Tsuneto LT, Probst CM, Hutz MH, et al. HLA class II diversity in seven Amerindian populations. Clues about the origins of the Ach. Tissue Antigens. 62(6), 512-526 (2003).
10. Excoffier L, Laval G, Schneider S: Arlequin ver. 3.0: an integrated software package for population genetics data analysis. Evol. Bioinform. Online 1, 47-50 (2005).
11. Lewontin RC: The interaction of selection and linkage. I. General considerations; heterotic models. Genetics. 49(1), 49-67 (1964).
12. Cavalli-Sforza LL, Menozzi P, Piazza A: The history and geography of human genes. Princeton University Press, NJ, USA (1994).
13. Salzano FM, Bortolini MC: The evolution and genetics of Latin American populations. Cambridge University Press, Cambridge, UK (2002).
14. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 3(2), 229-243 (2002).
15. Dorado P, Suarez-Kurtz G, Llerena A: Pharmacogenetics of cytochrome P450 in Hispanic populations. In: Pharmacogenomics in Admixed Populations. Suarez-Kurtz G (Ed.), Landes Bioscience, TX, USA, 60-74 (2007).
16. Parra EJ: Admixture In North America. In: Pharmacogenomics in Admixed Populations. Suarez-Kurtz G (Ed.), Landes Bioscience, TX, USA, 28-46 (2007).
17. Michaud V, Vanier MC, Brouillette D, et al. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin. Pharmacol. Ther. 83(5), 740-748 (2008). (Pubitemid 351556023)
18. Schelleman H, Chen Z, Kealey C, et al. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin. Pharmacol. Ther. 81(5), 742-747 (2007). (Pubitemid 46625114)
19. Gage B, Eby C, Johnson J, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008). (Pubitemid 38111225)
20. Aquilante CL, Langaee TY, Lopez LM, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79(4), 291-302 (2006).
21. Perini JA, Struchiner CJ, Silva-Assunção E, et al. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin. Pharmacol. Ther. (2008) (Epub ahead of print).
22. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14(13), 1745-1751 (2005).
23. Faucz FR, Probst CM, Petzl-Erler ML: Polymorphism of LMP2, TAP1, LMP7 and TAP2 in Brazilian Amerindians and Caucasoids: implications for the evolution of allelic and haplotypic diversity. Eur. J. Immunogenet. 27(1), 5-16 (2000).
24. Suarez-Kurtz G, Pena SDJ: Pharmacogenetics in the Brazilian population. In: Pharmacogenomics in Admixed Populations. Suarez-Kurtz G (Ed.), Landes Bioscience, TX, USA, 75-98 (2007).
25. Jaja C, Burke W, Thummel K, Edwards K, et al. Cytochrome p450 enzyme polymorphism frequency in indigenous and native American populations: a systematic review. Community Genet. 11(3), 141-149 (2008). (Pubitemid 351465617)
26. Gaspar PA, Hutz MH, Salzano FM, et al. Polymorphisms of CYP1A1, CYP2E1, GSTM1, GSTT1, and TP53 genes in Amerindians. Am. J. Phys. Anthropol. 119(3), 249-256 (2002).
27. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7), 2329-2333 (2005).
28. Geisen C, Watzka M, Sittinger K, et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost. 94(4), 773-779 (2005). (Pubitemid 41489236)
29. Obayashi K, Nakamura K, Kawana J, et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin. Pharmacol. Ther. 80(2), 169-178 (2006). (Pubitemid 44160690)
30. An overview of Amerindian populations in Brazil: Povos Indígenas no Brasil (accessed March 12, 2008) www.socioambiental.org/pib/index.html